Communiqués Satellos Bioscience Inc.

Actions

MSCL

CA80401L8033

Recherche biotechnologique et médicale

Marché Fermé - Toronto S.E. 21:47:06 28/09/2026			Varia. 5j.	Varia. 1 janv.
12,46 ^CAD	-0,36 %		-4,41 %	+57,26 %

24/09	Satellos obtient l’autorisation de la FDA pour sa demande d’autorisation de nouveau médicament expérimental contre la FSHD	MT
24/09	Satellos Bioscience Inc. annonce l’autorisation par la FDA de sa demande d’autorisation d’essai clinique (IND) pour le forazapadin dans la dystrophie musculaire facio-scapulo-humérale	CI

Communiqués

24/09	Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development	AQ
15/09	Satellos to Present at the 31st Annual Congress of the World Muscle Society	AQ
09/09	Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247	AQ
01/09	Satellos to Participate in Upcoming Investor Conferences	AQ
13/08	Satellos Bioscience: Q2 Earnings Snapshot	AQ
13/08	Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress	AQ
08/07	Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247	AQ
29/06	Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy	AQ
25/06	Satellos to Present Clinical Program Updates at ICNMD 2026	AQ
17/06	Satellos Bioscience Announces Results of Annual Meeting of Shareholders	AQ
27/05	Satellos to Participate in Upcoming Investor Conferences	AQ
15/05	Satellos Bioscience : First Quarter 2026 Financial Results and Operational Highlights	PU
15/05	Satellos Bioscience : First Quarter 2026 Management’s Discussion Analysis	PU
15/05	Satellos Bioscience: Q1 Earnings Snapshot	AQ
15/05	Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress	AQ
05/05	Investor Presentation 04/22/2026 00:00:00	PU
23/04	Satellos Bioscience : 2026 Bloom Burton & Co. Healthcare Investor Conference Presentation	PU
09/04	Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference	AQ
30/03	Satellos Reports 2025 Financial Results and Highlights Recent Company Progress	AQ
27/03	Satellos Bioscience: Q4 Earnings Snapshot	AQ
27/03	Satellos Bioscience : Fourth Quarter 2025 Financial Results and Operational Highlights	PU
27/03	Satellos Bioscience : Fourth Quarter 2025 Management’s Discussion Analysis	PU
27/03	Satellos Reports 2025 Financial Results and Highlights Recent Company Progress	AQ
10/03	Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference	AQ
24/02	Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference	BU